The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia

Cell Cycle

Volumn 8, Issue 21, 2009, Pages 3488-3492

  Chen, Yaoyu ^a   Li, Dongguang ^b   Li, Shaoguang ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b EDITH COWAN UNIVERSITY   (Australia)

Author keywords

Alox5; BCR ABL; Leukemic stem cells; Ph+ leukemia; Zileuton

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BCR ABL PROTEIN; CYCLOPAMINE; IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; ZILEUTON;

ARACHIDONATE 5 LIPOXYGENASE GENE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL RENEWAL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG INHIBITION; DRUG TARGETING; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE IDENTIFICATION; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA CELL; MICROARRAY ANALYSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; WILD TYPE;

MUS;

EID: 70449715255     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.21.9852     Document Type: Review

References (26)

1. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306:277-280 (Pubitemid 14232360)
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037 (Pubitemid 32267972)
3. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401. (Pubitemid 38938156)
4. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML. N Engl J Med 2004; 351:657-667 (Pubitemid 39063268)
5. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99:319-325
6. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701-4707 (Pubitemid 36857723)
7. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355:1253-1261
8. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev 2003; 3:895-902. (Pubitemid 37500174)
9. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer and cancer stem cells. Nature 2001; 414:105-111
10. Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. Cell 2008; 132:681-696 (Pubitemid 351253688)
11. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005; 15:494-501. (Pubitemid 41253469)
12. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Nat Acad Sci USA 2006; 103:16870-16875
13. Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009; 41:783-792
14. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423:409-414
15. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411:349-354 (Pubitemid 32467044)
16. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423:255-260 (Pubitemid 40852690)
17. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12:528-541 (Pubitemid 350199070)
18. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009; 458:776-779
19. Catalano A, Rodilossi S, Caprari P, Coppola V, Procopio A. 5-Lipoxygenase regulates senescencelike growth arrest by promoting ROS-dependent p53 activation. EMBO J 2005; 24:170-179 (Pubitemid 40188474)
20. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008; 9:162-176
21. + human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 2007; 25:3111-3120
22. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Nat Acad Sci USA 2006; 103:2794-2799 (Pubitemid 43306628)
23. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441:475-482 (Pubitemid 44050144)
24. Grisolano JL, O'Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Nat Acad Sci USA 2003; 100:9506-9511 (Pubitemid 37033958)
25. Shiraga H, Watanabe Y, Mori A. Guanidino compound levels in the serum of healthy adults and epileptic patients. Epilepsy Res 1991; 8:142-148
26. Hu Y, Chen Y, Douglas L, Li S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009; 23:109-116